Drug Profile
Research programme: targeted cancer diagnostics and therapeutics - ImaRx Therapeutics
Alternative Names: MRX 960Latest Information Update: 14 May 2007
Price :
$50
*
At a glance
- Originator ImaRx Therapeutics
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Oct 2003 Preclinical trials in Cancer diagnosis in USA (Injection)
- 31 Oct 2003 Preclinical trials in Cancer in USA (Injection)